Lymphoma tumor burden before chimeric antigen receptor T-Cell treatment: RECIL vs. Lugano vs. metabolic tumor assessment.

High tumor burden has emerged as a negative predictor of efficacy in chimeric antigen receptor T-cell therapy (CART) in patients with refractory or relapsed large B-cell lymphoma. This study analyzed the deviation among imaging-based tumor burden (TB) metrics and their association with progression-free (PFS) and overall survival (OS). In this single-center observational study, we included all consecutively treated patients receiving CD19 CART with available baseline PET-CT imaging. Imaging-based TB was determined based on response evaluation criteria in lymphoma (RECIL), the Lugano criteria, and metabolic tumor volume. Total, nodal and extranodal TB were represented, according to the respective criteria, by sum of longest diameters (TB 34 consecutive patients were included (median age: 67 years, 41% female) with total median baseline TB Pre-CART TB metrics vary significantly based on the assessment method, impacting their association with survival outcomes. The correlation between TB

Informations de copyright

Copyright © 2022 Winkelmann, Bücklein, Blumenberg, Rejeski, Ruzicka, Unterrainer, Schmidt, Dekorsy, Bartenstein, Ricke, von Bergwelt-Baildon, Subklewe and Kunz.

Déclaration de conflit d'intérêts

Author VB has received industry research support from Gilead, Novartis, Celgene, and Roche. Author KR declares having received research funding and travel support from Kite/Gilead and honoraria from Novartis. Author CS received travel support from Kite/Gilead. Author MB-B received research funding and honoraria from Novartis, Kite Pharma, Miltenyi Biotec, Mologen, MSD, Astellas, and Roche. Author MS received industry research support from Amgen, Gilead, Miltenyi Biotec, MorphoSys, Roche, and Seattle Genetics; served as a consultant or advisor to Amgen, Bristol Myers Squibb, Celgene, Gilead, Pfizer, Novartis, and Roche; is on the advisory boards of Amgen, Celgene, Gilead, Janssen, Novartis, Pfizer, and Seattle Genetics; and serves on the speaker’s bureau at Amgen, Celgene, Gilead, Janssen, and Pfizer. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.